EurekAlert: Using telehealth to transition diabetes inpatients to virtual care during COVID-19. “Data collected over a 15-week period showed that using virtual care to manage diabetes patients in the hospital does not have a negative impact on their glycemic outcomes. This study, aimed at reducing provider and patient exposure during the COVID-19 pandemic, has broader implications for implementing telehealth to diabetes care in remote locations and to limit the transmission of hospital-acquired infections.”
OneZero: A Black Market for Life-Saving Insulin Thrives on Social Media. “Insulin is an essential and life-saving drug used by 7.4 million people in the United States. Over the last few years, it’s become increasingly expensive. Between 2012 and 2016, the price of insulin effectively doubled for people with type one diabetes, with costs jumping from $239 to $475 per month, on average. These controversial and dramatic price hikes, singled out by presidential candidates like Bernie Sanders and Elizabeth Warren, have become symbols of a failing American healthcare system. They have also created a thriving online black market for insulin.”
Techdirt: Abbott Laboratories Sends Heavy-Handed Copyright Threat To Shut Down Diabetes Community Tool For Accessing Blood-Sugar Data. “A few months back there was a post on Diabettech about some code posted to GitHub. A patch to Abbott Laboratories’ LibreLink app allowed data from the same company’s FreeStyle Libre continuous monitor to be accessed by other apps running on a smartphone. In particular, it enabled the blood-sugar data to be used by a program called xDrip, which provides ‘sophisticated charting, customization and data entry features as well as a predictive simulation model.’ Innocent enough, you might think. But not according to Abbott Laboratories, which sent in the legal heavies waving the DMCA.” Heaven forbid people get as much access to and use of their own personal medical information as possible. Pllbbt.